Precision Medicine Software

Chapter Outlines

Chapter 2 is an executive summary of key insights captured in our research. It offers a high-level view on the current state of precision medicine software market and its likely evolution in the mid to long term.

Chapter 3 provides a general introduction to precision medicine and precision medicine software solutions and its historical evolution. It further includes a brief outline on the need for software solutions, along with information on the various patient monitoring related services offered by players engaged in this domain. Furthermore, it highlights prevalent advantages and key challenges associated with precision medicine software, featuring details related to the current and future trends in the domain.

Chapter 4 provides a detailed overview of the overall market landscape of players engaged in providing precision medicine software solutions, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, types of platforms (cloud-based, on-premises),  purpose of software (diagnosis, analysis, treatment), type of data handled (genomic data, clinical data, image data, omics data), therapeutic area (oncological disorders, cardiovascular disorders, neurological disorders, metabolic disorders), types of end users (healthcare providers, research and government institutes, pharmaceutical and biotech companies). 

Chapter 5 includes detailed profiles of the key players that are active in this domain. Each profile includes a brief overview of the company, its information on technology / service portfolio, recent developments and an informed future outlook.

Chapter 6 features a comprehensive company competitiveness analysis, highlighting prominent players among two peer groups (North America and Europe and Asia Pacific) that we came across during our research. The chapter provides a comparative analysis of the companies within each peer group on the basis of supplier strength (considering a company’s overall experience in the industry).

Chapter 7 provides an overview of the various patents related to precision medicine software solutions that have been filed / granted, since 2018. It highlights the key trends associated with these patents across various parameters, such as patent publication year, geographical location / patent jurisdiction, CPC symbols, emerging focus areas, type of organization, leading patent assignees and the leading players (in terms of number of patents filed). In addition, it includes a patent benchmarking analysis and a detailed valuation analysis.

Chapter 8 features an analysis of the recent partnerships inked between precision medicine software developers, during the period 2018-2021 Additionally, it includes a brief description of the various types of partnerships models (such as product / software integration agreement, service alliance, service agreement, product / software development agreement, full business acquisition, product / software distribution agreement, product / software utilization agreement, and product portfolio acquisition) that have been adopted by stakeholders engaged in this domain, during the period 2018-2021.

Chapter 9 provides an analysis of various investments made by players engaged in this domain based on several relevant parameters, such as year of investment, number of funding instances, amount invested and type of funding (such as, venture capital, private equity, secondary offerings, debt, initial public offering (IPO), other equity, seed, grant, and others), along with information on the most active players (in terms of number of funding instances and amount raised) and most active investors (in terms of number of funding instances). 

Chapter 10 features a proprietary 2×2 representation, highlighting the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.

Chapter 11 features a detailed market forecast analysis, highlighting the likely evolution of the market in the short to mid-term and long term, for the period 2021-2031. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] target therapeutic area (oncological disorders, cardiovascular disorders, neurological disorders, metabolic disorders), [B] key geographical regions (North America, Europe, Asia-Pacific) and [C] end user (healthcare providers, research & government institutes, pharmaceutical & biotech companies). 

Chapter 12 provides a detailed discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, along with a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall precision medicine software developers.

Chapter 13 is a summary of the entire report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 15 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY
2.1. Chapter Overview

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Precision Medicine
3.2.1. Evolution of Precision Medicine
3.2.2. Novel Approaches in Precision Medicine
3.2.2.1. Biomarkers and Decision Making
3.2.2.2. Genomics, Epigenetics and MicroRNAs as Emerging Biomarkers
3.2.2.3 Biomarker Multiplexing
3.2.2.4. Digital Biomarkers
3.2.2.5. Metabolomics

3.3. Key Technology Platforms
3.3.1. Cloud Based
3.3.2. On-Premises

3.4. Key Challenges Faced by Precision Medicine Software Developers
3.4.1. Unprecedented Data Volumes
3.4.2. Interpreting Data Deluge at the Level of Individual
3.4.3. Incorporation into the Clinic

3.5. Application Areas
3.6. Benefits of Precision Medicine over Traditional Treatment Modalities
3.6.1. Benefits to Patients
3.6.2. Benefits to Healthcare Providers

3.7. Future Perspectives

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Precision Medicine Software Developers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Region
4.2.4. Analysis by Status of Development
4.2.5. Analysis by Type of Platform
4.2.6. Analysis by Regulatory Accreditations
4.2.5. Analysis by Purpose of Software
4.2.6. Analysis by Type of Data Handled
4.2.7. Analysis by Therapeutic Area
4.2.8. Analysis by Type of End-User

4.3. Most Active Players: Analysis by Number of Software

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Precision Medicine Software Developers
5.2.1. AceTech
5.2.1.1. Company overview
5.2.1.2. Product portfolio
5.2.1.3. Recent Developments and Future Outlook

5.2.2. Ariel Precision Medicine 
5.2.2.1. Company Overview
5.2.2.2. Product Portfolio
5.2.2.3. Recent Developments and Future Outlook

5.2.3. C2i Genomics 
5.2.3.1. Company Overview
5.2.3.2. Product Portfolio
5.2.3.3. Recent Developments and Future Outlook

5.2.4. Genedata 
5.2.4.1. Company Overview
5.2.4.2. Product Portfolio
5.2.4.3. Recent Developments and Future Outlook

5.2.5. Inspirata 
5.2.5.1. Company Overview
5.2.5.2. Product Portfolio
5.2.5.3. Recent Developments and Future Outlook

5.2.6. IQVIA 
5.2.6.1. Company Overview
5.2.6.2. Product Portfolio
5.2.6.3. Recent Developments and Future Outlook

5.3. Additional Profiles
5.3.1. Fabric Genomics 
5.3.1.1. Company Overview
5.3.1.2. Product Portfolio
5.3.1.3. Recent Developments and Future Outlook

5.3.2. GenomOncology 
5.3.2.1. Company Overview
5.3.2.2. Product Portfolio
5.3.2.3. Recent Developments and Future Outlook

5.3.3. Human Longevity 
5.3.3.1. Company Overview
5.3.3.2. Product Portfolio
5.3.3.3. Recent Developments and Future Outlook

5.3.4. SOPHiA GENETICS
5.3.4.1. Company Overview
5.3.4.2. Product Portfolio
5.3.4.3. Recent Developments and Future Outlook

5.3.5. Syapse
5.3.5.1. Company Overview
5.3.5.2. Product Portfolio
5.3.5.3. Recent Developments and Future Outlook

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Company Competitiveness Analysis Based on Company size
6.2.1. Assumptions / Key Parameters
6.2.2. Methodology
6.2.3. Company Competitiveness Analysis: Small Companies
6.2.4. Company Competitiveness Analysis: Mid-sized Companies
6.2.5. Company Competitiveness Analysis: Large and Very Large Companies

6.3. Company Competitiveness Analysis Based on Geographical Region
6.3.1. Assumptions / Key Parameters
6.3.2. Methodology
6.3.3. Company Competitiveness Analysis: Companies in North America
6.3.4. Company Competitiveness Analysis: Companies in Europe, Asia-Pacific and Rest of the World

6.4. Key Players Based on Proprietary Scores

7. PATENT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Precision Medicine Software Developers: Patent Analysis
7.3.1. Analysis by Type of Patent
7.3.2. Analysis by Publication Year 
7.3.3. Analysis by Publication Year and Type of Patent
7.3.4. Analysis by Geography
7.3.4.1. Patent Analysis: North America Scenario
7.3.4.2. Patent Analysis: Europe Scenario
7.3.4.3. Patent Analysis: Asia-Pacific Scenario

7.3.5.  Analysis by CPC Symbols
7.3.6. Analysis by Emerging Focus Area
7.3.7. Most Active Players: Analysis by Number of Patents
7.3.8. Most Active Inventors: Analysis by Number of Patents
7.3.9. Analysis by Type of Organization
7.3.10. Patent Benchmarking Analysis
7.3.10.1. Analysis by Patent Characteristics
7.3.10.1.1. Tempus Labs and GenomSys
7.3.10.1.2. Other Leading Patent Assignees

7.3.11. Patent Valuation Analysis
7.3.12. Legal Status Analysis
7.3.12.1. Analysis by Legal Status
7.3.12.2. Analysis by Geography and Legal Status

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Precision Medicine Software Developers: List of Partnerships
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Focus Area
8.3.5. Analysis by Year of Partnership and Focus Area
8.3.6. Analysis by Type of Partnership and Focus Area
8.3.7. Analysis by Therapeutic Area
8.3.8. Analysis by Type of Partnership and Type of Platform
8.3.9. Analysis by Type of Partnership and Type of Data Handled

8.3.10. Analysis by Region
8.3.10.1. Continent-wise Distribution
8.3.10.2. Intercontinental and Intracontinental Distribution
8.3.10.3. Country-wise Distribution

8.3.11. Most Active Players: Analysis by Number of Partnerships

9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Precision Medicine Software Developers: Funding and Investment Analysis
9.3.1 Analysis by Number of Funding Instances by Year
9.3.2. Analysis of Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Regional Analysis by Amount Invested
9.3.5. Analysis by Year and Type of Funding
9.3.6. Most Active Players: Analysis by Number of Funding Instances and Amount Invested
9.3.7. Key Investors: Analysis by Number of Instances
9.3.8. Analysis by Purpose of Investment
9.3.9. Analysis by Type of Data Handled
9.3.10. Analysis by Therapeutic Area

10. ATTRACTIVENESS COMPETETIVENESS MATRIX
10.1. Chapter Overview
10.2. AC Matrix: Overview
10.2.1. Strong Business Segments
10.2.2. Average Business Segments
10.2.3. Weak Business Segments

10.3. AC Matrix: Analytical Methodology
10.4. AC Matrix: Precision Medicine Software Developers for Different Therapeutic Areas
10.5. AC Matrix: Precision Medicine Software Developers in Different Regions

11. MARKET FORECAST
11.1. Chapter Overview
11.2. Forecast Methodology and Assumptions
11.3. Global Precision Medicine Software Developers Market, 2021-2032
11.3.1. Precision Medicine Software Developers Market, 2021-2032: Analysis by Therapeutic Area
11.3.1.1. Precision Medicine Software Developers Market for Oncological Disorders, 2021-2032
11.3.1.2. Precision Medicine Software Developers Market for Neurological Disorders, 2021-2032
11.3.1.3. Precision Medicine Software Developers Market for Cardiovascular Disorders, 2021-2032
11.3.1.4. Precision Medicine Software Developers Market for Metabolic Disorders, 2021-2032
11.3.1.5. Precision Medicine Software Developers Market for Other Disorders, 2021-2032

11.3.2. Precision Medicine Software Developers Market, 2021-2032: Analysis by Type of End-User
11.3.2.1. Precision Medicine Software Developers Market for Healthcare Providers, 2021-2032
11.3.2.2. Precision Medicine Software Developers Market for Hospitals, 2021-2032

11.3.3. Precision Medicine Software Developers Market, 2021-2032: Analysis by Region
11.3.3.1. Precision Medicine Software Developers Market in North America, 2021-2032
11.3.3.2. Precision Medicine Software Developers Market in Europe, 2021-2032
11.3.3.3. Precision Medicine Software Developers Market in Asia-Pacific and Rest of the World, 2021-2032

12. SWOT ANALYSIS
12.1. Chapter Overview
12.2. Strengths
12.3. Weaknesses
12.4. Opportunities
12.5. Threats
12.6. Comparison of SWOT Factors
12.7. Concluding Remarks

13. CONCLUDING REMARKS
13.1. Chapter Overview

14. APPENDIX I: TABULATED DATA

15. APPENDIX II: LIST OF COMPANIES

List Of Figures

Figure 2.1. Executive Summary: Developer Landscape
Figure 2.2. Executive Summary: Partnerships and Collaborations
Figure 2.3. Executive Summary: Funding and Investments
Figure 2.4. Executive Summary: Patent Analysis
Figure 2.5. Executive Summary: Market Forecast
Figure 3.1. Evolution of Precision Medicine
Figure 3.2. Applications of Precision Medicine
Figure 4.1. Precision Medicine Software Developers: Distribution by Year of Establishment
Figure 4.2. Precision Medicine Software Developers: Distribution by Company Size
Figure 4.3. Precision Medicine Software Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.4. Precision Medicine Software Developers: Distribution by Location of Headquarters (Country-wise)
Figure 4.5. Precision Medicine Software Developers: Distribution by Company Size and Region
Figure 4.6. Precision Medicine Software Developers: Distribution by Year of Establishment, Company Size and Location of Headquarters
Figure 4.7. Precision Medicine Software Applications: Distribution by Status of Development
Figure 4.8. Precision Medicine Software Applications: Distribution by Status of Development and Region
Figure 4.9. Precision Medicine Software Applications: Distribution by Type of Platform
Figure 4.10. Precision Medicine Software Applications: Distribution by Regulatory Accreditation Received
Figure 4.11. Precision Medicine Software Applications: Distribution by Purpose of Software Applications
Figure 4.12. Precision Medicine Software Applications: Distribution by Type of Data Handled
Figure 4.13. Precision Medicine Software Applications: Distribution by Status of Development and Type of Data Handled
Figure 4.14. Precision Medicine Software Applications: Distribution by Therapeutic Area
Figure 4.15. Precision Medicine Software Applications: Distribution by Therapeutic Area and Status of Development
Figure 4.16. Precision Medicine Software Applications: Distribution by Type of Data Handled and Therapeutic Area
Figure 4.17. Precision Medicine Software Applications: Distribution by Type of End-User
Figure 4.18. Most Active Players: Distribution by Number of Software Applications
Figure 6.1. Company Competitiveness Analysis: Small Companies Scenario
Figure 6.2. Company Competitiveness Analysis: Mid-sized Companies Scenario
Figure 6.3. Company Competitiveness Analysis: Large and Very Large Companies Scenario
Figure 6.4. Company Competitiveness Analysis: Companies in North America
Figure 6.5. Company Competitiveness Analysis: Companies in Europe, Asia-Pacific and Rest of the World
Figure 6.6. Key Players Based on Proprietary Scores
Figure 7.1. Patent Analysis: Distribution by Type of Patent
Figure 7.2. Patent Analysis: Distribution by Publication Year, 2018-2021
Figure 7.3. Patent Analysis: Distribution of Granted Patents by Publication Year
Figure 7.4. Patent Analysis: Distribution by Geography (Continent-wise)
Figure 7.5. Patent Analysis: North America Scenario (Region-wise)
Figure 7.6. Patent Analysis: Europe Scenario (Region-wise)
Figure 7.7. Patent Analysis: Asia-Pacific Scenario (Region-wise)
Figure 7.8. Patent Analysis: Distribution by CPC Classification
Figure 7.9. Patent Analysis: Distribution by Emerging Focus Area
Figure 7.10. Most Active Players: Distribution by Number of Patents
Figure 7.11. Most Active Inventors: Distribution by Number of Patents
Figure 7.12. Overall Intellectual Property Portfolio: Distribution by Type of Organization
Figure 7.13. Patent Benchmarking Analysis: Tempus Labs and GenomSys
Figure 7.14. Patent Benchmarking Analysis: Other Leading Players
Figure 7.15. Patent Analysis: Distribution by Patent Age
Figure 7.16. Patent Analysis: Patent Relative Valuation
Figure 7.17. Patent Analysis: Distribution by Legal Status
Figure 7.18. Patent Analysis: Distribution by Legal Status and Geography
Figure 8.1. Partnerships: Distribution by Year of Partnership
Figure 8.2. Partnerships: Distribution by Type of Partnership
Figure 8.3. Partnerships: Distribution by Year and Type of Partnership
Figure 8.4. Partnerships: Distribution by Focus Area
Figure 8.5. Heat Map: Distribution by Year of Partnership and Focus Area
Figure 8.6. Partnerships: Distribution by Type of Partnership and Focus Area
Figure 8.7. Partnerships: Distribution by Therapeutic Area
Figure 8.8. Partnerships: Distribution by Type of Partnership and Type of Platform
Figure 8.9. Partnerships: Distribution by Type of Partnership and Type of Data Handled
Figure 8.10. Partnerships: Continent-wise Distribution
Figure 8.11. Partnerships: Intercontinental and Intracontinental Agreements
Figure 8.12. Partnerships: Country-wise Distribution
Figure 8.13. Most Active Players: Distribution by Number of Partnerships
Figure 9.1. Funding and Investment Analysis: Distribution by Year of Funding (2018-2021)
Figure 9.2. Funding and Investment Analysis: Distribution of Amount Invested by Year (USD Million)
Figure 9.3. Funding and Investment Analysis: Distribution Type of Funding, 2018-2021
Figure 9.4. Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, 2018-2021 (USD Million)
Figure 9.5. Funding and Investment Analysis: Summary of Investments, 2018-2020 (USD Million)
Figure 9.6. Funding and Investment Analysis: Distribution by Geography
Figure 9.7. Funding and Investment Analysis: Distribution of Instances by Geography 2018-2020
Figure 9.8. Funding and Investment Analysis: Distribution of Instances by Year and Type of Funding, 2018-2021
Figure 9.9. Funding and Investment Analysis: Distribution by Year, Type of Funding and Amount Invested, 2018-2021 (USD Million)
Figure 9.10. Most Active Players: Distribution by Number of Funding Instances
Figure 9.11. Most Active Investors: Distribution by Amount Raise (USD Million)
Figure 9.12. Funding and Investment Analysis: Distribution by Type of Investor
Figure 9.13. Funding and Investment Analysis: Distribution by Purpose of Investment
Figure 9.14. Funding and Investment Analysis: Distribution by Type of Data Handled
Figure 9.15. Funding and Investment Analysis: Distribution by Therapeutic Area
Figure 10.1. AC Matrix: Pictorial Representation
Figure 10.2. AC Matrix: Precision Medicine Software Developers for Various Therapeutic Areas
Figure 10.3. AC Matrix: Precision Medicine Software Developers in Regions
Figure 11.1. Global Precision Medicine Software Developers Market, 2021-2032 (USD Million)
Figure 11.2. Precision Medicine Software Developers Market: Distribution by Therapeutic Area, 2022 and 2032
Figure 11.3. Precision Medicine Software Developers Market for Oncological Disorders, 2021-2032 (USD Million)
Figure 11.4. Precision Medicine Software Developers Market for Neurological Disorders, 2021-2032 (USD Million)
Figure 11.5. Precision Medicine Software Developers Market for Cardiovascular Disorders, 2021-2032 (USD Million)
Figure 11.6. Precision Medicine Software Developers Market for Metabolic Disorders, 2021-2032 (USD Million)
Figure 11.7. Precision Medicine Software Developers Market for Other Disorders, 2021-2032 (USD Million)
Figure 11.8. Precision Medicine Software Developers Market: Distribution by Types of End-users, 2022 and 2032 (USD Million)
Figure 11.9. Precision Medicine Software Developers Market for Healthcare Providers, 2021-2032 (USD Million)
Figure 11.10. Precision Medicine Software Developers Market for Hospitals, 2021-2032 (USD Million)
Figure 11.11. Precision Medicine Software Developers Market: Distribution by Geography, 2022 and 2032 (USD Million)
Figure 11.12. Precision Medicine Software Developers Market in North America, 2021-2032 (USD Million)
Figure 11.13. Precision Medicine Software Developers Market in Europe, 2021-2032 (USD Million)
Figure 11.14. Precision Medicine Software Developers Market in Asia-Pacific and Rest of the World, 2021-2032 (USD Million)
Figure 12.1. Precision Medicine Software Developers: SWOT Analysis
Figure 12.2. Comparison of SWOT Factors: Harvey Ball Analysis
Figure 13.1. Concluding Remarks: Current Market Landscape
Figure 13.2. Concluding Remarks: Patent Analysis
Figure 13.3. Concluding Remarks: Partnerships and Collaborations
Figure 13.4. Concluding Remarks: Funding and Investment Analysis
Figure 13.5. Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 4.1. Precision Medicine Software Developers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 4.2. Precision Medicine Software Applications: Information on Software Applications, Status of Development, and Compliance
Table 4.3. Precision Medicine Software Applications: Information on Therapeutic Area, Type of Data Handled, Purpose of Software and Type of End-User
Table 5.1. AceTech: Company Overview
Table 5.2. AceTech: Product Portfolio
Table 5.3. Ariel Precision Medicine: Company Overview
Table 5.4. Ariel Precision Medicine: Product Portfolio
Table 5.5. Ariel Precision Medicine: Recent Developments and Future Outlook
Table 5.6. C2i Genomics: Company Overview
Table 5.7. C2i Genomics: Product Portfolio
Table 5.8. C2i Genomics: Recent Developments and Future Outlook
Table 5.9. Genedata: Company Overview
Table 5.10. Genedata: Product Portfolio
Table 5.11. Genedata: Recent Developments and Future Outlook
Table 5.12. Inspirata: Company Overview
Table 5.13. Inspirata: Product Portfolio
Table 5.14. IQVIA: Company Overview
Table 5.15. IQVIA: Product Portfolio
Table 5.16. IQVIA: Recent Developments and Future Outlook
Table 5.17. Fabric Genomics: Company Overview
Table 5.18. Fabric Genomics: Product Portfolio
Table 5.19. GenomOncology: Company Overview
Table 5.20. GenomOncology: Product Portfolio
Table 5.21. Human Longevity: Company Overview
Table 5.22. Human Longevity: Product Portfolio
Table 5.23. SOPHiA GENETICS: Company Overview
Table 5.24. SOPHiA GENETICS: Product Portfolio
Table 5.25. SOPHiA GENETICS: Recent Developments and Future Outlook
Table 5.26. Syapse: Company Overview
Table 5.27. Syapse: Product Portfolio
Table 5.28. Syapse: Recent Developments and Future Outlook
Table 7.1. Patent Analysis: List of Top CPC Symbols
Table 7.2. Patent Analysis: Summary of Benchmarking Analysis
Table 7.3. Patent Analysis: Various Categorization based on Weighted Scores
Table 7.4. Patent Analysis: List of Leading Patents (in terms of highest relative valuation)
Table 8.1. Partnerships and Collaborations: List of Partnerships
Table 8.2. Partnerships and Collaborations: Information on Focus Area, Therapeutic Area, Type of Platform and Type of Data Handled
Table 9.1. Precision Medicine Software Developers Market: Funding and Investments, 2018-2021
Table 9.2 Funding and Investment Analysis: Summary of Investments
Table 9.3 Funding and Investment Analysis: Summary of Venture Capital Round
Table 9.4 Fundings and Investments: Information on Purpose of Investment, Type of Data Handled and Therapeutic Area
Table 14.1. Precision Medicine Software Developers: Distribution by Year of Establishment
Table 14.2. Precision Medicine Software Developers: Distribution by Company Size
Table 14.3. Precision Medicine Software Developers: Distribution by Location of Headquarters (Region-wise)
Table 14.4. Precision Medicine Software Developers: Distribution by Location of Headquarters (Country-wise)
Table 14.5. Precision Medicine Software Developers: Distribution by Company Size and Region
Table 14.6. Precision Medicine Software Developers: Distribution by Year of Establishment, Company Size and Location of Headquarters
Table 14.7. Precision Medicine Software Applications: Distribution by Status of Development
Table 14.8. Precision Medicine Software Applications: Distribution by Status of Development and Region
Table 14.9. Precision Medicine Software Applications: Distribution by Type of Platform
Table 14.10. Precision Medicine Software Applications: Distribution by Regulatory Accreditations Received
Table 14.11. Precision Medicine Software Applications: Distribution by Type of Data Handled
Table 14.12. Precision Medicine Software Applications: Distribution by Status of Development and Type of Data Handled
Table 14.13. Precision Medicine Software Applications: Distribution by Therapeutic Area
Table 14.14. Precision Medicine Software Applications: Distribution by Therapeutic Area and Status of Development
Table 14.15. Precision Medicine Software Applications: Distribution by Type of Data Handled and Therapeutic Area
Table 14.16. Precision Medicine Software Developers: Distribution by Type of End-User
Table 14.17. Most Active Players: Distribution by Number of Software Applications
Table 14.18. Patent Analysis: Distribution by Type of Patent
Table 14.19. Patent Analysis: Distribution by Publication Year, 2018-2021
Table 14.20. Patent Analysis: Distribution of Granted Patents by Publication Year
Table 14.21. Patent Analysis: Distribution by Geography (Continent-wise)
Table 14.22. Patent Analysis: North America Scenario (Region-wise)
Table 14.23. Patent Analysis: Europe Scenario (Region-wise)
Table 14.24. Patent Analysis: Asia-Pacific Scenario (Region-wise)
Table 14.25. Most Active Players: Distribution by Number of Patents
Table 14.26. Most Active Inventors: Distribution by Number of Patents
Table 14.27. Overall Intellectual Property Portfolio: Distribution by Type of Organization
Table 14.28. Patent Analysis: Distribution by Patent Age
Table 14.29. Patent Analysis: Patent Relative Valuation
Table 14.30. Patent Analysis: Distribution by Legal Status
Table 14.31. Patent Analysis: Distribution by Legal Status and Geography
Table 14.32. Partnerships: Distribution by Year of Partnership
Table 14.33. Partnerships: Distribution by Type of Partnership
Table 14.34. Partnerships: Distribution by Year and Type of Partnership
Table 14.35. Partnerships: Distribution by Focus Area
Table 14.36. Partnerships: Distribution by Year of Partnership and Focus Area
Table 14.37. Partnerships: Distribution by Type of Partnership and Focus Area
Table 14.38. Partnerships: Distribution by Therapeutic Area
Table 14.39. Partnerships: Country-wise Distribution
Table 14.40. Most Active Players: Distribution by Number of Partnerships
Table 14.41. Funding and Investment Analysis: Distribution by Year of Funding (2018-2021)
Table 14.42. Funding and Investment Analysis: Distribution of Amount Invested by Year (USD Million)
Table 14.43. Funding and Investment Analysis: Distribution of Type of Funding, 2018-2021
Table 14.44. Funding and Investment Analysis: Distribution of Amount Invested by the Type of Funding, 2018-2021 (USD Million)
Table 14.45. Funding and Investment Analysis: Summary of Investments, 2018-2020 (USD Million)
Table 14.46. Funding and Investment Analysis: Distribution by Geography
Table 14.47. Funding and Investment Analysis: Distribution of Instances by Geography 2018-2020
Table 14.48. Funding and Investment Analysis: Distribution of Instances by Year and Type of Funding, 2018-2021
Table 14.49. Funding and Investment Analysis: Distribution of Instances by Year, Type of Funding and Amount Invested, 2018-2021 (USD Million)
Table 14.50. Most Active Players: Distribution by Number of Funding Instances
Table 14.51. Most Active Investors: Distribution by Amount Raise (USD Million)
Table 14.52. Funding and Investment Analysis: Distribution by Type of Investor
Table 14.53. Funding and Investment Analysis: Distribution by Purpose of Investment
Table 14.54. Funding and Investment Analysis: Distribution by Type of Data Handled
Table 14.55. Funding and Investment Analysis: Distribution by Therapeutic Area
Table 14.56. Global Precision Medicine Software Developers Market, 2021-2032 (USD Million)
Table 14.57. Precision Medicine Software Developers Market: Distribution by Therapeutic Area, 2022 and 2032
Table 14.58. Precision Medicine Software Developers Market for Oncological Disorders, 2021-2032 (USD Million)
Table 14.59. Precision Medicine Software Developers Market for Neurological Disorders, 2021-2032 (USD Million)
Table 14.60. Precision Medicine Software Developers Market for Cardiovascular Disorders, 2021-2032 (USD Million)
Table 14.61. Precision Medicine Software Developers Market for Metabolic Disorders, 2021-2032 (USD Million)
Table 14.62. Precision Medicine Software Developers Market for Other Disorders, 2021-2032 (USD Million)
Table 14.63. Precision Medicine Software Developers Market: Distribution by Types of End-users, 2022 and 2032 (USD Million)
Table 14.64. Precision Medicine Software Developers Market for Healthcare Providers, 2021-2032 (USD Million)
Table 14.65. Precision Medicine Software Developers Market for Hospitals, 2021-2032 (USD Million)
Table 14.66. Precision Medicine Software Developers Market: Distribution by Geography, 2022 and 2032 (USD Million)
Table 14.67. Precision Medicine Software Developers Market in North America, 2021-2032 (USD Million)
Table 14.68. Precision Medicine Software Developers Market in Europe, 2021-2032 (USD Million)
Table 14.69. Precision Medicine Software Developers Market in Asia-Pacific and Rest of the World , 2021-2032 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report.

1. 2bPrecise
2. 2nd.MD
3. 4D Path
4. 83North
5. AB Enzymes
6. Abu Dhabi Health Data Services
7. ACE & Company
8. AceTech
9. Admera Health
10. Advaita
11. AdventHealth
12. Adventist Health
13. Aetna
14. AG Mednet
15. Agilent Technologies
16. Ainnova Tech
17. AIQ Solutions
18. Alexandria Venture Investments
19. AliveAndKickn
20. Allscripts
21. Ally Bridge Group
22. Altis Labs
23. Altium Capital
24. Alychlo
25. AMedSU
26. American Heart Association
27. American Society of Clinical Oncology
28. Amgen
29. AMITA Health
30. aMoon
31. AMRA Medical
32. PathWest Laboratory Medicine
33. ARCH Venture Partners
34. Ariel Precision Medicine
35. ARUP Laboratories
36. Ascension Ventures
37. Asset Management Ventures
38. Astarte Medical
39. AstraZeneca
40. ATW Partners
41. Audacy
42. Australian BioCommons
43. Australian Research Data Commons (ARDC)
44. Axiom Associates
45. Babylon Health
46. Baillie Gifford
47. Bain Capital Ventures
48. Bainbridge Health
49. Balderton Capital
50. Barts Health NHS Trust
51. Bayer
52. BC Platforms
53. Beacon Capital
54. Belgian Society of Medical Oncology 
55. BenevolentAI
56. Biocept 
57. BioVariance
58. Blueprint Medicines
59. Boehringer Ingelheim Venture Fund
60. Brainomix
61. Breakthrough Genomics
62. Briban Invest
63. Bristol Myers Squibb
64. Broad Institute
65. Business Development Bank of Canada
66. C2i Genomics
67. Caesar
68. Apple
69. Cancer Genetics
70. CancerIQ
71. Capital Midwest Fund
72. Caris Life Sciences
73. Casdin Capital
74. Catipult.AI
75. Clayton, Dubilier & Rice (CD&R)
76. Celgene
77. Centana Growth Partners
78. CENTOGENE
79. Centro Hospitalar Lisboa Ocidental 
80. Cergentis
81. Children’s Brain Tumor Tissue Consortium
82. Chimera Partners
83. Cigna Ventures
84. Circle Cardiovascular Imaging
85. Claremont Creek Ventures
86. Cofactor Genomics
87. Cohesic
88. Colle Capital
89. Color
90. Community Health Network
91. ConCR
92. Connect Ventures
93. Cornerstone Specialty Network  
94. Cortex
95. Crohn’s & Colitis Foundation
96. CureMatch
97. Curii
98. Data4Cure
99. Datavant
100. Decentralized Trials & Research Alliance
101. Dell Technologies
102. Diagnomics
103. Diagnostic Laboratory Services
104. Dian Diagnostics
105. Discovery Life Sciences
106. DNA Compass
107. DNAnexus
108. Dolby Family Ventures
109. DoseMe (Acquired by Tabula Rasa HealthCare)
110. DrChrono
111. Driehaus Capital Management
112. Duquesne Family Office
113. Echo Health Ventures
114. Eiffel Investment
115. Elekta
116. Elysia Capital
117. Emory Healthcare
118. Endeavour Vision
119. e-NIOS 
120. EnvoyAI
121. Epic App Orchard
122. EpigeneticsRx
123. Esplanade Ventures
124. Essen University
125. Eurazeo
126. European Organisation for Research and Treatment of Cancer (EORTC)
127. European Specialist Investment
128. EW Healthcare Partners
129. Fabric Genomics
130. Famille C Invest
131. Farsight Genome Systems
132. Feist-Weiller Cancer Center
133. First Round Capital
134. Flatiron Health
135. Fluidigm
136. Flywheel
137. Foresite Capital
138. Foundation Medicine
139. F-Prime Capital
140. Franklin Templeton
141. Friends of Cancer Research
142. GE Healthcare
143. Geisinger
144. Genedata
145. General Catalyst
146. Generation Investment Management
147. Genetic Alliance
148. Genetic Technologies
149. GeneXplain
150. Genmab
151. Genome Medical
152. GenomOncology
153. Genomelink
154. Genomenon
155. Genomics England
156. Genomind
157. GenomOncology
158. GenomSys
159. Genospace
160. GenXys Health Care Systems
161. Gilead Sciences
162. GNS Healthcare
163. Golden Helix
164. Green Shield Canada
165. GreenM
166. GV
167. Hamilton Health Sciences
168. Healix
169. Health Catalyst Capital
170. Health Innovation Manchester
171. Healthgen AI
172. HealthQuad
173. Hearst Health
174. Heritas Capital
175. Highmark Health
176. Hitachi
177. Hôpital Foch
178. Houston Methodist
179. Huami
180. HudsonAlpha Institute
181. Human Longevity
182. Hygea Precision Medicine 
183. Hyperfine
184. Ibex Medical Analytics
185. IBM
186. International Development Association (IDA)
187. Idinvest Partners
188. iGlobe Partners
189. Illumina
190. Illumina Ventures
191. Imaging Biometrics
192. Imaginostics
193. ImmunityBio
194. Indiana Clinical and Translational Sciences Institute
195. Indiana University
196. Industrifonden
197. iNDX.Ai
198. InformedDNA
199. Innovatus Capital Partners
200. Inova Health System
201. InsightRX
202. Inspirata
203. Integrated DNA Technologies
204. Intellihealth
205. Interactive Biosoftware
206. Intermountain Healthcare
207. Intero Life Sciences
208. Intertrust Technologies
209. IntrinsiQ Specialty Solutions
210. IQVIA
211. IRA Capital
212. Janssen
213. JDRF
214. JiNan Danjier
215. Kamet Ventures
216. Kinship
217. Koninklijke Philips
218. Konyang University Hospital
219. Kura Oncology
220. LabCorp
221. Lifebit
222. LifeOmic Health
223. Livongo
224. LSS
225. LunaPBC
226. M2Gen
227. MacroGenics
228. Marienhaus Hospital
229. Mary Crowley Cancer Research
230. Mayo Clinic
231. McKesson Ventures
232. medASTUTE
233. Medfusion
234. Medical University of South Carolina
235. Medidata
236. MedImpact
237. Medimsight
238. Medipredict
239. Medley Genomics
240. Merck
241. Merck Global Health Innovation Fund
242. Merstal
243. Merus
244. Metabolon
245. Microsoft
246. MidCap Financial
247. MindX Sciences
248. Mission Bio
249. Moffitt Cancer Center
250. Molecular Health
251. MolecularMatch
252. MTIP
253. Multiple Myeloma Research Foundation
254. Murfreesboro Medical Clinic & SurgiCenter
255. mymo.AI
256. Myriad Genetics
257. NantHealth
258. NantOmics 
259. Nashville Veterans Affairs Hospital
260. Natera
261. National Cancer Center
262. National Cancer Institute
263. National Institute of Health
264. NeoGenomics 
265. New Enterprise Associates
266. Nextrans
267. NFX
268. NHS
269. National Instruments (NI)
270. National Institutes of Health (NIH)
271. Nimbus Synergies
272. Northpond Ventures
273. NorthShore University HealthSystem
274. Northwell Health
275. Northwest Firefighters Benefits Trust
276. Notable
277. Novartis
278. Novo Holdings
279. NovogeneAIT Genomics
280. NYU Grossman School of Medicine
281. Octopus Ventures
282. Ohio State University
283. Olea Medical
284. Oncora Medical
285. OncXerna Therapeutics
286. OneOncology
287. Oracle
288. Orion Health
289. Osage University Partners
290. Outcomes4Me
291. Oxford University
292. Pancreatic Cancer Action Network
293. Paragon Genomics
294. Parexel
295. Parkwalk Advisors
296. Pentech Ventures
297. Perceiv AI
298. Perceptive Advisors
299. Personal Genome Diagnostics
300. Pfizer
301. Pharmatics
302. PhenoTips®
303. Phillips
304. Phosphorus 
305. PierianDx
306. Pillar Biosciences
307. Pinnacle
308. PipelineRx
309. Planven Entrepreneur Ventures
310. Precision Digital Health
311. Precision for Medicine
312. Precision Health Informatics 
313. Precision Health Software
314. Premier
315. Preon Capital
316. Prisma Health
317. Proscia
318. Prudential Financial
319. Psyche Systems
320. Psychiatry-UK
321. Pygar
322. Q² Solutions
323. QIAGEN
324. Qlucore
325. QMENTA
326. QNA Dx
327. Quadria Capital
328. Quantgene
329. QUBIS
330. Quest Diagnostics
331. Qynapse
332. Renalytix AI
333. Renown Health
334. RetInSight
335. Revelation Alpine
336. Revolution Growth
337. Roche
338. Rock River Capital Partners
339. 30Ventures
340. RTI International
341. Russell Microcap Index
342. RxGenomix
343. RXVIP Concierge
344. Safeguard Scientifics
345. San Francisco Otolaryngology
346. Sanford Health
347. Sano Genetics
348. Sanofi
349. SAP
350. SCA Robotics
351. ScienceVision
352. ScreenPoint Medical
353. Section 32
354. Sentieon
355. Seoul National University Hospital
356. Sequoia
357. Seven Bridges
358. Sidney Kimmel Cancer Center
359. Siemens Healthineers
360. Sierra Ventures
361. SimplicityBio
362. SJF Ventures
363. Social Capital
364. SocialGenomics
365. Sonraí Analytics
366. SOPHiA GENETICS
367. Spanish Lung Cancer
368. St. Joseph’s/Candler
369. St. Jude Children's Research Hospital
370. Stanford Health Care
371. Stone Checker
372. Strand Life Sciences
373. Stryker
374. Studio Management
375. Sun Life
376. Sunquest Information Systems
377. Susman Ventures
378. Sutter Health
379. Swisscom Ventures
380. Syapse
381. T. Rowe Price
382. Tabula Rasa HealthCare
383. Takeda
384. Taliaz
385. Teamsters
386. TeamViewer
387. Techstart Ventures
388. Teladoc Health
389. TELUS Ventures
390. Tempus Labs
391. Ten Coves Capital
392. TeraRecon
393. Terumo
394. The Mark Foundation for Cancer Research
395. Parker Institute
396. Thermo Fisher Scientific
397. Thomas Jefferson University
398. TIGAR Health Technologies
399. Tiger Global Management
400. Tiny VC
401. Tmunity Therapeutics
402. Topcon Healthcare
403. TPG Biotech
404. Translational Sciences Institute
405. Translational Software
406. Trapelo Health
407. Trialbee
408. TriCore Reference Laboratories
409. Triesta Sciences
410. TwinStrand Biosciences
411. Twist Bioscience 
412. Tydo
413. UK Research and Innovation
414. uMETHOD
415. UnitedHealthcare
416. University Hospital of Augsburg
417. University of California
418. University of Chicago
419. University of Missouri Health Care
420. University of Pittsburgh Medical Center (UPMC)
421. US Orthopedic Alliance
422. Vanderbilt-Ingram Cancer Center
423. Vanderbilt University Medical Center
424. Varian
425. Verily Life Sciences
426. Vicinity
427. Vidence
428. VigiLanz 
429. Viking Global Investors
430. Visiopharm
431. Welfare Fund of Philadelphia
432. Wellcome Sanger Institute
433. Wisconsin Investment Partners
434. Genuity Science (formerly known as WuXi NextCODE)
435. XIFIN
436. Y Combinator
437. YouScript
438. Zero Childhood Cancer
439. ZS Associates